Last reviewed · How we verify
Myoview (TECHNETIUM TC 99M TETROFOSMIN)
Myoview works by accumulating in the heart muscle and emitting gamma rays that are detected by a scanner, allowing for visualization of blood flow.
Myoview (Technetium TC 99M Tetrofosmin) is a radioactive diagnostic agent used for radionuclide myocardial perfusion studies. It is a small molecule modality developed by GE Healthcare, which is still owned by the company. Myoview is used to evaluate blood flow to the heart muscle, helping diagnose coronary artery disease. It was FDA-approved in 1996 for this specific indication. As a patented product, Myoview is not yet available as a generic.
At a glance
| Generic name | TECHNETIUM TC 99M TETROFOSMIN |
|---|---|
| Sponsor | GE HealthCare |
| Drug class | Radioactive Diagnostic Agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1996 |
Mechanism of action
Imagine your heart muscle as a sponge that absorbs a special dye. Myoview is that dye, which gets absorbed by the heart muscle and then emits a signal that can be detected by a special camera. This signal helps doctors see how well blood is flowing to the heart muscle.
Approved indications
- Radionuclide myocardial perfusion study
Common side effects
- Radioisotope scan abnormal
- No adverse event
- Scan myocardial perfusion abnormal
Key clinical trials
- Evaluation of the Diagnostic Performance of Dynamic Myocardial Perfusion Scintigraphy in Comparison With Invasive Intracoronary FFR Measurement, in the Assessment of Significant Residual Coronary Stenosis After Acute Coronary Syndrome: Dyna-MI Pilot Study. (NA)
- Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve
- Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF) (NA)
- A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (PHASE2)
- Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (PHASE3)
- Cardiac Autonomic Function in Women with Microvascular Coronary Dysfunction (NA)
- A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. (PHASE3)
- Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Myoview CI brief — competitive landscape report
- Myoview updates RSS · CI watch RSS
- GE HealthCare portfolio CI